A. No treatment decision is appropriate until the NGS results return B. Begin carboplatin, pemetrexed, and pembrolizumab while waiting for the NGS results C. Begin cemiplimab monotherapy and utilize NGS results for 2nd-line decision making D. Begin erlotinib plus ramucirumab and utilize NGS results for 2nd-line decision making E. Unsure

A. Pembrolizumab monotherapy B. Carboplatin, pemetrexed, nivolumab, and ipilimumab C. Sotorasib D. Sotorasib and nivolumab E. Unsure

A. Chemotherapy toxicity rarely leads to treatment discontinuation, while monotherapy PD1 inhibitor toxicity commonly leads to discontinuation B. Immunotherapy has multiple drug interactions that can lead to increased toxicity, while few drug interactions exist for chemotherapy C. Cycle 1 toxicity with immunotherapy predicts the tolerability moving forward, but chemotherapy-related toxicity is less predictable D. Rapid diagnosis and early intervention minimize an immunotherapy-related toxicity like diarrhea, but not chemotherapy-associated diarrhea E. Unsure

A. They predict poor outcomes B. They are all dose dependent C. They can be permanent D. Their time to onset is predictable E. Unsure

A. Give all patients a prescription for prednisone with cycle 1 to take when needed B. Educate clinical and non-clinical staff about irAEs and how to manage patients seeking help C. Create a standalone clinic to see and manage all immunotherapy patients D. Connect patients with a specialty pharmacy to manage treatment-related toxicity needs E. Unsure